Elinzanetant Eases Menopause Hot Flashes and Night Sweats Fast

Across four Phase III trials involving women from very different backgrounds, the drug elinzanetant reduced moderate-to-severe hot flashes and night sweats as early as week 1, with benefits holding steady for up to 50 weeks. A 2026 review in Maturitas, led by Dr. JoAnn Pinkerton of the University of Virginia, pooled the evidence from the OASIS clinical trial program to ask one question: does this drug work consistently for everyone?

Why Blocking Neurokinin Receptors Stops Hot Flashes

To understand why this drug class exists, it helps to know what actually triggers a hot flash. Hot flashes originate in the hypothalamus, where a population of neurons called KNDy neurons sits near the body’s thermoregulatory control center. These neurons release a signaling peptide called neurokinin B, which binds to neurokinin-3 (NK3) receptors — and to a lesser extent neurokinin-1 (NK1) receptors — to influence how tightly the brain regulates core body temperature.

When estrogen declines at menopause, KNDy neurons become hyperactive and the thermoneutral zone (the temperature range in which you feel neither too hot nor too cold) narrows dramatically. Small temperature changes that once went unnoticed — a warm drink, a stuffy room — now trigger full heat-dumping responses: flushing, sweating, and the nighttime wakening that so many women describe. Elinzanetant blocks NK1 and NK3 receptors, essentially quieting the overactive signal that narrows the thermoneutral zone.

This mechanism explains two things the trial data show. First, the drug works independently of estrogen, so it can be used by breast cancer survivors whose endocrine therapy (aromatase inhibitors or tamoxifen) makes hormone therapy off-limits. Second, improved sleep is not just a byproduct of fewer night sweats — the neurokinin system also intersects with brain pathways governing sleep-wake regulation.

Four Trials, One Consistent Result Across Very Different Women

The review covered OASIS-1 through -4. OASIS-1, -2, and -3 enrolled women with moderate-to-severe vasomotor symptoms from natural or surgical menopause; surgical menopause often produces more abrupt and intense symptoms because estrogen drops overnight rather than gradually. OASIS-4 focused specifically on women whose hot flashes were caused by endocrine therapy for breast cancer — a group that has historically had the fewest treatment options.

Results lined up across all four studies. Hot flash frequency fell significantly versus placebo by week 4 in OASIS-1, -2, and -4 (and descriptively in OASIS-3), and by week 12 every trial showed significant reductions. Symptom severity also dropped significantly at weeks 4 and 12 in OASIS-1 and -2. Sleep disturbance, measured with the validated PROMIS Sleep Disturbance Short Form 8b, improved as early as week 1, with significant reductions at week 12 in OASIS-1, -2, and -4. Total scores on the Menopause-specific Quality of Life questionnaire improved on the same timeline. Elinzanetant was generally well tolerated throughout.

One honest caveat: because each trial tested a specific population, subgroup differences within trials (for example, by age or symptom duration) were not the focus of this review. Consistency across populations is reassuring, but it does not replace individualized clinical judgment.

A Non-Hormonal Option That Still Acts on the Brain — Not Just the Symptoms

Hormone therapy remains the most effective treatment for most women with bothersome hot flashes, and it treats the underlying estrogen decline. But roughly a third of women cannot or prefer not to use it, including breast cancer survivors and women with certain clotting or liver histories. Older non-hormonal options — SSRIs, SNRIs, gabapentin — help modestly and carry their own side effects, from sexual dysfunction to drowsiness.

Elinzanetant occupies a different position. It does not raise estrogen, so it does not carry the risks associated with systemic hormone use, yet it acts on the specific neural circuit driving hot flashes rather than merely blunting perception of them. Notably, the sleep improvements were a measured, significant secondary outcome — relevant given evidence that the estrogen decline affects sleep quality broadly, not only through night sweats.

What to Discuss With Your Clinician

• Candidates: Women with moderate-to-severe hot flashes — generally seven or more per day — whether from natural menopause, ovary removal, or breast cancer endocrine therapy.
• Timeline for effect: Benefit may appear within the first week; full assessment typically occurs by week 4 to 12.
• Sleep and quality of life: If night wakening and daytime fatigue accompany your hot flashes, these were specifically measured and improved in the trials.
• Not a substitute for hormone therapy’s other benefits: Elinzanetant does not address bone density, long-term brain health, or cardiovascular effects of estrogen loss. Women in early menopause may still need separate strategies for those risks.

Frequently Asked Questions

What is a neurokinin receptor antagonist?

It is a drug that blocks neurokinin-1 and neurokinin-3 receptors in the brain’s hypothalamus, calming the neural circuit that narrows the body’s temperature comfort zone and triggers hot flashes — without affecting estrogen levels.

How quickly does elinzanetant work for hot flashes?

In the OASIS trials, significant reductions versus placebo appeared as early as week 1 in some studies, were clear at week 4, and were maintained for up to 50 weeks.

Can breast cancer survivors take elinzanetant?

Yes — OASIS-4 specifically tested women whose hot flashes were caused by endocrine therapy for breast cancer and found the same significant benefits seen in menopause due to other causes.

Does elinzanetant help sleep as well as hot flashes?

Yes. Sleep disturbance, measured with a validated PROMIS questionnaire, improved across all four trials as early as week 1, with significant reductions versus placebo at week 12.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42537360/
https://pubmed.ncbi.nlm.nih.gov/42515941/
https://pubmed.ncbi.nlm.nih.gov/42508870/
https://pubmed.ncbi.nlm.nih.gov/42284819/
https://pubmed.ncbi.nlm.nih.gov/42160911/